CystoSmart™, an AI software tool for bladder tumor detection in patients undergoing screening and surveillance endoscopic examination of the bladder is brand agnostic and compatible with flexible and ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Cystoscopy without the aid of urinary markers is the most cost-effective strategy for detecting recurrence of non-invasive bladder cancer, according to researchers. In a study that examined five ...

CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that utilizes artificial intelligence ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

Nearly 84,000 Americans will receive a bladder cancer diagnosis this year, yet most people remain unaware of the early warning signs that could save their lives. This silent disease often masquerades ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the disease.The ongoing SunRISe-3 trial (NCT05714202) is testing TAR-200 head-to-head ...